[go: up one dir, main page]

GB202219154D0 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof

Info

Publication number
GB202219154D0
GB202219154D0 GBGB2219154.8A GB202219154A GB202219154D0 GB 202219154 D0 GB202219154 D0 GB 202219154D0 GB 202219154 A GB202219154 A GB 202219154A GB 202219154 D0 GB202219154 D0 GB 202219154D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2219154.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metacurum Biotech AB
Original Assignee
Metacurum Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacurum Biotech AB filed Critical Metacurum Biotech AB
Priority to GBGB2219154.8A priority Critical patent/GB202219154D0/en
Publication of GB202219154D0 publication Critical patent/GB202219154D0/en
Priority to CN202380087175.8A priority patent/CN120548327A/en
Priority to KR1020257024360A priority patent/KR20250123919A/en
Priority to PCT/EP2023/086443 priority patent/WO2024133132A1/en
Priority to AU2023413523A priority patent/AU2023413523A1/en
Priority to EP23833774.5A priority patent/EP4637927A1/en
Priority to JP2025536120A priority patent/JP2026501220A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB2219154.8A 2022-12-19 2022-12-19 Antibodies and uses thereof Ceased GB202219154D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2219154.8A GB202219154D0 (en) 2022-12-19 2022-12-19 Antibodies and uses thereof
CN202380087175.8A CN120548327A (en) 2022-12-19 2023-12-18 Anti-TGFβ receptor 1 antibodies and uses thereof
KR1020257024360A KR20250123919A (en) 2022-12-19 2023-12-18 Anti-TGFbeta receptor 1 antibodies and uses thereof
PCT/EP2023/086443 WO2024133132A1 (en) 2022-12-19 2023-12-18 Anti-tgfbeta receptor 1 antibodies and uses thereof
AU2023413523A AU2023413523A1 (en) 2022-12-19 2023-12-18 Anti-tgfbeta receptor 1 antibodies and uses thereof
EP23833774.5A EP4637927A1 (en) 2022-12-19 2023-12-18 Anti-tgfbeta receptor 1 antibodies and uses thereof
JP2025536120A JP2026501220A (en) 2022-12-19 2023-12-18 Anti-TGFβ receptor 1 antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2219154.8A GB202219154D0 (en) 2022-12-19 2022-12-19 Antibodies and uses thereof

Publications (1)

Publication Number Publication Date
GB202219154D0 true GB202219154D0 (en) 2023-02-01

Family

ID=85035753

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2219154.8A Ceased GB202219154D0 (en) 2022-12-19 2022-12-19 Antibodies and uses thereof

Country Status (7)

Country Link
EP (1) EP4637927A1 (en)
JP (1) JP2026501220A (en)
KR (1) KR20250123919A (en)
CN (1) CN120548327A (en)
AU (1) AU2023413523A1 (en)
GB (1) GB202219154D0 (en)
WO (1) WO2024133132A1 (en)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
AU2378402A (en) 2000-11-06 2002-05-15 Imp Cancer Res Tech Imaging, diagnosis and treatment of disease
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
BR0316101A (en) 2002-11-07 2005-09-27 Immunogen Inc Anticd33 antibodies and process for treating acute meloid leukemia using the same.
DK1565491T3 (en) 2002-11-20 2010-07-19 Cancer Rec Tech Ltd Antibodies that bind to human magic roundabout (MRI), polypeptides and their uses for inhibiting angiogenesis
RU2007108716A (en) 2004-09-10 2008-10-20 Вайет (Us) HUMANIZED ANTIBODIES TO 5T4 ANTIGEN AND CONJUGATES OF THE HUMANIZED ANTIBODIES TO 5T4 ANTIGEN WITH KALIHEAMICIN
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors
WO2012125623A2 (en) * 2011-03-14 2012-09-20 Ludwig Institute For Cancer Research Ltd. Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
US11643459B2 (en) * 2016-03-11 2023-05-09 Scholar Rock, Inc. TGFβ1-binding immunoglobulins and use thereof

Also Published As

Publication number Publication date
CN120548327A (en) 2025-08-26
WO2024133132A9 (en) 2024-08-22
EP4637927A1 (en) 2025-10-29
WO2024133132A1 (en) 2024-06-27
JP2026501220A (en) 2026-01-14
KR20250123919A (en) 2025-08-18
AU2023413523A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
IL308808A (en) Anti-ccr8 antibodies and uses thereof
GB2610467B (en) Anti-CLL1 antibody and application thereof
GB202017058D0 (en) Antibodies and uses thereof
IL319931A (en) Anti-cd122 antibodies and uses thereof
IL307267A (en) Anti-cd122 antibodies and uses thereof
IL310662A (en) Anti-cd161 antibodies and uses thereof
IL307940A (en) Anti-adgre2 antibodies and uses thereof
AU2022298850A1 (en) Anti-ccr8 antibodies and uses thereof
EP4294840A4 (en) Anti-cd30l antibodies and uses thereof
IL320586A (en) Anti-trem2 antibody and uses thereof
IL317391A (en) Novel anti-lilrb4 antibodies and uses thereof
IL308382A (en) Novel anti-cd276 antibodies and the uses thereof
IL307939A (en) Anti-clec12a antibodies and uses thereof
IL316510A (en) Anti-b7h3 antibody and uses thereof
IL312584A (en) Anti-vista antibodies and uses thereof
IL320972A (en) Anti-tfr1 antibodies and uses thereof
IL317849A (en) Anti-slc34a2 monoclonal antibodies and uses thereof
EP4437000A4 (en) Anti-trem2 antibody and uses thereof
IL307233A (en) Anti-sema3a antibodies and uses thereof
IL310028A (en) Antibody and use thereof
IL319145A (en) Novel anti-lilrb2 antibodies and uses thereof
IL304412A (en) Antibodies against cd112r and uses thereof
IL310810A (en) Anti-acvr2a antibodies and uses thereof
IL308198A (en) Anti-il-27 antibodies and uses thereof
IL325218A (en) Antibodies and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)